Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

OBT and GSK Forge Multi-Target Cancer Collaboration Using OGAP Platform

Fineline Cube Dec 13, 2025
Company Deals

Insilico Licenses AI‑Designed ISM4808 PHD Inhibitor to TaiGen in Two‑Digit Million Dollar Greater China Deal

Fineline Cube Dec 13, 2025
Company Deals

Bleecker Bio (Formation) Licenses Lynk’s CNS‑Penetrant TYK2 Inhibitor LNK01006 in $605 M Deal

Fineline Cube Dec 11, 2025
Company Deals

Juncell Therapeutics Files for HKEX IPO, Pioneering Chemo‑Free TIL Therapy for Solid Tumors

Fineline Cube Dec 11, 2025
Company Deals

Relation Therapeutics and Novartis Forge $1.7 Billion Alliance for AI‑Driven Atopic Disease Targets

Fineline Cube Dec 11, 2025
Policy / Regulatory

NHSA 2025 Drug Lists Add 114 Medical Insurance Drugs, 19 Commercial

Fineline Cube Dec 8, 2025
Company Drug

Sino Biopharm’s Culmerciclib Wins NMPA Approval as First CDK2/4/6 Inhibitor for Breast Cancer

Fineline Cube Dec 13, 2025
Company Drug

Lobemilast (Y‑3) NDA Accepted by NMPA as First Multi‑Target Stroke Neuroprotectant

Fineline Cube Dec 12, 2025
Policy / Regulatory

Chinese Pharmacists Association Releases Draft VBP Drug Management Guidelines for Public Feedback

Fineline Cube Jul 26, 2022

The Chinese Pharmacists Association (CPA) has released the “National Volume-based Procurement (VBP) Drug Management Expert...

Company Deals

3D Medicines Files IPO Prospectus for Hong Kong Listing

Fineline Cube Jul 26, 2022

China-based oncology specialist 3D Medicines has published its initial public offering (IPO) prospectus with the...

Company Drug

I-Mab Doses First Patient in Global Phase I Study for TJ-CD4B in Solid Tumors

Fineline Cube Jul 25, 2022

I-Mab (NASDAQ: IMAB), a Nasdaq-listed company since 2020, announced that the first patient has been...

Company Deals Drug

Rona Therapeutics Licenses Sanofi’s siRNA Platform for Global Development

Fineline Cube Jul 25, 2022

Shanghai-based RNA therapeutics specialist Rona Therapeutics has entered into a licensing agreement with French pharmaceutical...

Company Digital

ApolloBio Corp. Initiates Pre-Clinical Study for ABC-5100 Nanobody Against COVID-19

Fineline Cube Jul 25, 2022

ApolloBio Corp. (NEEQ:430187) announced the initiation of a pre-clinical study for its novel broad-spectrum anti-COVID-19...

Company Deals

InventisBio Raises USD 308M in Shanghai STAR IPO, Valued at USD 1.54B

Fineline Cube Jul 25, 2022

China-based biotech firm InventisBio (SHA: 688382) has completed an initial public offering (IPO) of 115...

Policy / Regulatory

NMPA Releases 56th Batch of GQCE Reference Drugs, Including 14 Injectables

Fineline Cube Jul 25, 2022

The National Medical Products Administration (NMPA) has released the 56th batch of reference drugs for...

Company Deals

MobiDrop Raises USD 14.8M in Series A+ to Expand Single-Cell Product Pipeline

Fineline Cube Jul 25, 2022

China-based MobiDrop (Zhejiang) Co., Ltd has reportedly raised close to RMB 100 million (USD 14.8...

Company Drug

Luye Pharma’s LY01005 Meets Phase III Trial Goals in Breast Cancer Treatment

Fineline Cube Jul 25, 2022

China-based Luye Pharma Group (HKG: 2186) announced that its Phase III clinical study for LY01005...

Company Deals

ZGC Shuimu Medtech Raises RMB 100M in Series A+ Round Led by Yijing Capital

Fineline Cube Jul 25, 2022

Beijing-based ZGC Shuimu Medical Technology Services Group, China’s first private third-party medical device testing institution,...

Company Deals

Innovita Biological Technology’s IPO Raises USD 131.3M for POCT Expansion

Fineline Cube Jul 25, 2022

Innovita Biological Technology Co., Ltd, a Beijing-based point-of-care testing (POCT) specialist, is set to make...

Company Drug

Fidia Farmaceutici’s Hyalubrix 60 Shows Promise in Treating Arthropathy at Hainan Hospital

Fineline Cube Jul 25, 2022

Italy-based Fidia Farmaceutici S.p.A announced that its Hyalubrix 60, a prefilled syringe with sodium hyaluronate...

Company Deals

Linno Pharmaceuticals Raises USD 14.78M for Blood-Brain Barrier Drug Delivery Tech

Fineline Cube Jul 22, 2022

Shanghai-based rare disease specialist Linno Pharmaceuticals Inc. has reportedly raised close to RMB 100 million...

Company Deals

Frontier Biotech Raises USD 51.4M to Advance COVID-19 Drug FB2001

Fineline Cube Jul 22, 2022

China-based Frontier Biotechnologies Inc. (SHA: 688221) announced plans to raise RMB 270 million (USD 51.4...

Company Deals

Curatia Medical Raises Tens of Millions in Funding Co-led by Hidea Investment

Fineline Cube Jul 22, 2022

Curatia Medical Ltd, a vascular interventional therapy developer with operations in Silicon Valley, California, and...

Company Deals

Novaremed AG Licenses NRD.E1 to NeuroFront for Greater China Development

Fineline Cube Jul 22, 2022

Switzerland-based Novaremed AG has entered into a licensing agreement with China’s NeuroFront (Shanghai) Co., Ltd,...

Drug

Ascentage Pharma’s Olverembatinib Receives Health Canada Approval for Phase Ib Study

Fineline Cube Jul 22, 2022

Suzhou-based Ascentage Pharma (HKG: 6855) announced that it has received approval from Health Canada to...

Company Drug

Junshi Biosciences’ Toripalimab Receives EC Orphan Drug Designation for NPC

Fineline Cube Jul 22, 2022

China-based Junshi Biosciences (HKG: 1877, SHA: 688180) announced that its PD-1 inhibitor Toripalimab (trade name:...

Company Deals

Yifeng Pharmacy Chain to Establish New Company with Tangshan Deshuntang

Fineline Cube Jul 22, 2022

China-based Yifeng Pharmacy Chain Co., Ltd (SHA: 603939) announced that its subsidiary, Shijiazhuang Xinxing Pharmacy...

Company Drug

Ji Xing Pharmaceuticals Enrolls First Patient in OC-01 Phase III Study for Dry Eye

Fineline Cube Jul 22, 2022

Shanghai-based Ji Xing Pharmaceuticals, backed by RTW Investments, announced that the first patient has been...

Posts pagination

1 … 576 577 578 … 596

Recent updates

  • OBT and GSK Forge Multi-Target Cancer Collaboration Using OGAP Platform
  • Lilly to Invest Over $6 Billion in Alabama GLP‑1 Manufacturing Hub for Orforglipron
  • Sino Biopharm’s Culmerciclib Wins NMPA Approval as First CDK2/4/6 Inhibitor for Breast Cancer
  • Insilico Licenses AI‑Designed ISM4808 PHD Inhibitor to TaiGen in Two‑Digit Million Dollar Greater China Deal
  • Lobemilast (Y‑3) NDA Accepted by NMPA as First Multi‑Target Stroke Neuroprotectant
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

OBT and GSK Forge Multi-Target Cancer Collaboration Using OGAP Platform

Company

Lilly to Invest Over $6 Billion in Alabama GLP‑1 Manufacturing Hub for Orforglipron

Company Drug

Sino Biopharm’s Culmerciclib Wins NMPA Approval as First CDK2/4/6 Inhibitor for Breast Cancer

Company Deals

Insilico Licenses AI‑Designed ISM4808 PHD Inhibitor to TaiGen in Two‑Digit Million Dollar Greater China Deal

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.